Home | Politics | Advisories | FDA Issues Warning Re Magic Power Coffee

FDA Issues Warning Re Magic Power Coffee

FDA Issues Warning Re Magic Power Coffee

The FDA has issued a warning that consumers be wary of Magic Power Coffee, a product that is currently being marketed as an aphrodisiac for both men and women.

In actuality, it may work; a chemical found in the coffee is similar to sildenafil, the active ingredient in Viagara, the popular drug prescribed for erectile dysfunction. 
The problem however, is that the chemical, hydroxythiohomosildenafil, can interact with prescription medications, causing a significant drop in blood pressure.  The FDA is particularly concerned about such chemical reactions in men who are taking prescription medications containing nitrates, such as nitroglycerin.

In a statement posted on the agency’s website, Deborah M. Autor, the director of the FDA’s Center for Drug Evaluation and Research, Office of Compliance, states, "Because this product is an instant coffee labeled as an ‘all natural dietary supplement,’ consumers may assume it is harmless and poses no health "In fact, Magic Power Coffee can cause serious harm.”
The announcement further states that there have been several products marketed as dietary supplements specifically for sexual enhancement that actually contain undeclared active ingredients of FDA approved drugs or analogs of approved drugs, which disqualifies them as “dietary supplements.”

In an earlier statement, the FDA announced that these “problematic products,” which are marketed and sold online, seem to be increasing.  Following is a partial list of some of these “drugs”:

*Actra-RX
*Actra-SX
*Libidus
*Nasutra
*Neophase
*Vigor-25
*Yilishen
*Zimaxx
*4EVERON
*Liviro3
*Lycium Barbarum L.
*Adam Free
*Rhino V Max
*V. Max

The FDA recommends immediate disposal of these products if you have purchased them.
 
While the agency has not learned of any adverse events surrounding Magic Power Coffee, they are urging consumers to report any problems they may have experienced with it to the MedWatch program.